Drug Developers Facing "Unsettled" Period Of 5 To 10 Years As CER Environment Evolves, FDA's Woodcock Says
Executive Summary
The growing emphasis on comparative effectiveness research as well as the many unknowns on how the process is going to evolve could create a decade of unsettlement for drug development, FDA's Janet Woodcock said